As of November 6, 2026, Candel Therapeutics, Inc. is a publicly traded company (Nasdaq: CADL). The largest holder reporting an active stake on Schedule 13D is Paul B. Manning, a director, at 7.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include RTW Investments (8.8%), BlackRock (6.6%) (Schedule 13D/A, March 18, 2026).
Is this your company?
About to sign with, pay or invest in Candel Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Candel Therapeutics, Inc. a real, registered company?
- Candel Therapeutics, Inc. files with the SEC under CIK 1841387 (its SEC filings).
- Its shares are listed under the ticker CADL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Needham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CANDEL THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Martine Zimmermann, Director (Form 8-K filed 2026-09-10). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-27).
Who are Candel Therapeutics, Inc.'s owners and officers?
Candel Therapeutics, Inc.: incorporated in Delaware; business address in Needham, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-09-10).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 6.6% |
| Schedule 13G, 2026-05-15 | Rtw Investments, LP | 8.8% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 4.2% |
| Schedule 13D/A, 2026-03-18 | Paul B Manning | 7.9% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.2% |
Questions about who owns Candel Therapeutics, Inc.
Who owns Candel Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Candel Therapeutics, Inc.: Rtw Investments, LP (8.8%, Schedule 13G, filed 2026-05-15), Paul B Manning (7.9%, Schedule 13D/A, filed 2026-03-18) and Blackrock, Inc. (6.6%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of Candel Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Candel Therapeutics, Inc. on this page are Rtw Investments, LP (8.8%), Paul B Manning (7.9%) and Blackrock, Inc. (6.6%).
When did Rtw Investments, LP buy into Candel Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Rtw Investments, LP on this page is the Schedule 13G, filed 2026-05-15, reporting 8.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Candel Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Candel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Candel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-10 | Martine Zimmermann | Director | appointed | 2026-09-08 |
Which insiders own Candel Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 5,748,279 shares (7.5% of shares outstanding), 1,681,000 held directly and 4,067,279 indirectly (Form 4, 2026-02-26).
- , a director: 546,863 shares (0.71% of shares outstanding), held indirectly through By GTAM1 2012 LLC and 1 other (Form 4, 2025-06-26).
- , the chief executive and a director: 113,321 shares (0.15% of shares outstanding) (Form 4, 2026-09-11).
- , a director: 102,271 shares (0.13% of shares outstanding), 38,032 held directly and 64,239 indirectly (Form 4, 2025-06-26).
- , the chief scientific officer: 77,362 shares (0.10% of shares outstanding) (Form 4, 2026-07-01).
Shares outstanding: 76,518,565 as of 2026-08-06, from the company's latest SEC cover page.
How much has Candel Therapeutics, Inc. raised?
No fundraising or offering filing from Candel Therapeutics, Inc. is on file with us.
Keep reading
More on Candel Therapeutics, Inc. and the records around it.
Candel Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Jul 2026
Companies that share a holder
- Paul B Manning also filed stake reports on 2 other companies: LIQUIDIA CORP (Aug 2026), Verrica Pharmaceuticals Inc. (Nov 2025)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/candel-therapeutics